Press Releases

Year

Sep 01 2016

Intec Pharma Reports First Half 2016 Financial Results

Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016. Highlights of the first six months of 2016 and recent weeks

Aug 04 2016

Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies

Phase 1 clinical trial to begin in first quarter 2017 Intec Pharma Ltd. (Nasdaq:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its

Jun 03 2016

Intec Pharma Announces Planned Management Changes

JERUSALEM, June 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, the company's Chief Financial Officer, has

May 31 2016

Intec Pharma Receives Approval for US$5.2 Million Grant

JERUSALEM, May 31, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the Israeli National Authority for

May 16 2016

Intec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors

JERUSALEM, May 16, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the board of directors of the company

May 03 2016

Intec Pharma Appoints VP of Clinical and Regulatory Affairs

JERUSALEM, May 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs. "Ms. Strauss-Levy has 15 years of experience in clinical

Apr 06 2016

Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea

JERUSALEM, Israel, April 6, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean

Apr 04 2016

Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients

JERUSALEM, April 4, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for its lead product candidate, the Accordion Pill

Mar 17 2016

Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors

JERUSALEM, ISRAEL--(Marketwired - Mar 17, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr.

Mar 14 2016

Intec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results

JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the year ended

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Next page
Last page

Displaying 61 - 70 of 81